SLFN11-mediated tRNA regulation induces cell death by disrupting proteostasis in response to DNA-damaging agents.

DNA-damaging agents (DDAs) have long been used in cancer therapy. However, the precise mechanisms by which DDAs induce cell death are not fully understood and drug resistance remains a major clinical challenge. Schlafen 11 (SLFN11) was identified as the gene most strongly correlated with the sensitivity to DDAs based on mRNA expression levels.

Candidate genes in canine hepatocellular carcinoma for molecular targeted therapy.

Objectives: Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the expression of target genes.

Computed tomography may detect liver infiltration of canine diffuse hepatic lymphoma.

Background: In dogs, hepatic lymphoma is characterized by neoplastic lymphocyte infiltration into the liver. Reports on the computed tomography (CT) findings of the liver for canine hepatic lymphoma are few, with only one study of multiple liver lesions type.

Objectives: The purpose of this study was to retrospectively assess the CT findings of the liver in canine diffuse hepatic lymphoma.

Implantation of Human-Induced Pluripotent Stem Cell-Derived Cartilage in Bone Defects of Mice.

Although bone has an innate capacity for repair, clinical situations such as comminuted fracture, open fracture, or the surgical resection of bone tumors produce critical-sized bone defects that exceed the capacity and require external intervention. Initiating endochondral ossification (EO) by the implantation of a cartilaginous template into the bone defect is a relatively new approach to cure critical-sized bone defects. The combination of chondrogenically primed mesenchymal stromal/stem cells and artificial scaffolds has been the most extensively studied approach for inducing endochondral bone formation in bone defects.